Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 21 | 2022 | 7702 | 0.960 |
Why?
|
| Motor Cortex | 2 | 2015 | 117 | 0.860 |
Why?
|
| Brain Mapping | 5 | 2017 | 644 | 0.800 |
Why?
|
| Brain Neoplasms | 12 | 2022 | 4849 | 0.700 |
Why?
|
| Glioma | 5 | 2015 | 1963 | 0.650 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2018 | 1648 | 0.400 |
Why?
|
| Hand | 1 | 2012 | 170 | 0.390 |
Why?
|
| Brain | 6 | 2018 | 4113 | 0.330 |
Why?
|
| Neuroimaging | 1 | 2012 | 403 | 0.330 |
Why?
|
| Astrocytoma | 1 | 2010 | 321 | 0.310 |
Why?
|
| Glioblastoma | 4 | 2022 | 1797 | 0.290 |
Why?
|
| Speech | 2 | 2017 | 133 | 0.260 |
Why?
|
| Wernicke Area | 1 | 2017 | 11 | 0.160 |
Why?
|
| Meningeal Neoplasms | 3 | 2015 | 441 | 0.160 |
Why?
|
| Neuronavigation | 1 | 2017 | 47 | 0.150 |
Why?
|
| Molecular Imaging | 1 | 2018 | 185 | 0.140 |
Why?
|
| Cerebral Veins | 1 | 2016 | 28 | 0.140 |
Why?
|
| Spinal Cord Compression | 1 | 2017 | 151 | 0.130 |
Why?
|
| Contrast Media | 4 | 2016 | 1472 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 577 | 0.130 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 50 | 0.130 |
Why?
|
| Language | 1 | 2017 | 309 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 216 | 0.130 |
Why?
|
| Skull Base | 1 | 2016 | 199 | 0.120 |
Why?
|
| Middle Aged | 21 | 2018 | 86204 | 0.120 |
Why?
|
| Genomics | 3 | 2022 | 2738 | 0.110 |
Why?
|
| Spinal Diseases | 2 | 2011 | 125 | 0.110 |
Why?
|
| Laser Therapy | 1 | 2017 | 411 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 4367 | 0.110 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 510 | 0.100 |
Why?
|
| Adult | 19 | 2018 | 77950 | 0.100 |
Why?
|
| Spinal Neoplasms | 1 | 2017 | 631 | 0.100 |
Why?
|
| Radiation Injuries | 2 | 2011 | 1411 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 164 | 0.100 |
Why?
|
| Reference Values | 1 | 2012 | 1099 | 0.090 |
Why?
|
| Gene Expression | 1 | 2018 | 3570 | 0.090 |
Why?
|
| Parathyroid Neoplasms | 1 | 2011 | 185 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2016 | 1529 | 0.090 |
Why?
|
| Brain Diseases | 2 | 2003 | 403 | 0.080 |
Why?
|
| Image Enhancement | 3 | 2016 | 561 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 215 | 0.080 |
Why?
|
| Female | 19 | 2018 | 141928 | 0.080 |
Why?
|
| Male | 19 | 2018 | 123000 | 0.080 |
Why?
|
| Humans | 26 | 2022 | 261506 | 0.080 |
Why?
|
| Aged | 14 | 2018 | 70117 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 592 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 1283 | 0.080 |
Why?
|
| Young Adult | 6 | 2018 | 21445 | 0.070 |
Why?
|
| Adenoma | 1 | 2011 | 716 | 0.070 |
Why?
|
| Median Neuropathy | 1 | 2006 | 4 | 0.070 |
Why?
|
| Software | 1 | 2013 | 1321 | 0.070 |
Why?
|
| Retrospective Studies | 9 | 2022 | 37905 | 0.070 |
Why?
|
| Lipomatosis | 1 | 2006 | 24 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2011 | 7551 | 0.070 |
Why?
|
| Fingers | 1 | 2006 | 120 | 0.060 |
Why?
|
| Muscle Weakness | 1 | 2006 | 116 | 0.060 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 442 | 0.060 |
Why?
|
| Hamartoma | 1 | 2006 | 115 | 0.060 |
Why?
|
| Patient Positioning | 2 | 2017 | 195 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 612 | 0.060 |
Why?
|
| Spine | 1 | 2004 | 293 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 4744 | 0.050 |
Why?
|
| Choroid Plexus | 1 | 2002 | 31 | 0.050 |
Why?
|
| Echo-Planar Imaging | 1 | 2002 | 73 | 0.050 |
Why?
|
| Cerebral Ventricles | 1 | 2002 | 98 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2003 | 335 | 0.050 |
Why?
|
| Bevacizumab | 3 | 2011 | 938 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2017 | 2292 | 0.050 |
Why?
|
| Cysts | 1 | 2002 | 197 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1533 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 29902 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2007 | 1248 | 0.040 |
Why?
|
| Melanoma | 1 | 2015 | 5317 | 0.040 |
Why?
|
| Necrosis | 2 | 2011 | 580 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 1375 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 3441 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 344 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2017 | 316 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 2 | 2011 | 3976 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3821 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2017 | 232 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 665 | 0.030 |
Why?
|
| Adolescent | 4 | 2018 | 31252 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 187 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2017 | 239 | 0.030 |
Why?
|
| Mutation | 1 | 2015 | 15179 | 0.030 |
Why?
|
| Veins | 1 | 2016 | 157 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 700 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2010 | 10035 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2022 | 2295 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2011 | 3251 | 0.030 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 14289 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 15862 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 4971 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2003 | 1870 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 5437 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 10331 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2011 | 68 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 172 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2011 | 186 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2003 | 2278 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 245 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 437 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2010 | 89 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 460 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 980 | 0.020 |
Why?
|
| Prognosis | 2 | 2018 | 21713 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 256 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 361 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 436 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 1183 | 0.020 |
Why?
|
| Meningioma | 1 | 2011 | 289 | 0.020 |
Why?
|
| Capsules | 1 | 2007 | 53 | 0.020 |
Why?
|
| Anorexia | 1 | 2007 | 143 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 6009 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 7222 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 2588 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2003 | 6550 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 7789 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2015 | 32848 | 0.020 |
Why?
|
| Spinal Cord Diseases | 1 | 2004 | 90 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 1544 | 0.010 |
Why?
|
| Mice | 2 | 2018 | 34495 | 0.010 |
Why?
|
| Models, Structural | 1 | 2002 | 103 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 2002 | 94 | 0.010 |
Why?
|
| Time Factors | 2 | 2007 | 12926 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 12873 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 846 | 0.010 |
Why?
|
| Hydrocephalus | 1 | 2002 | 217 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 1351 | 0.010 |
Why?
|
| Animals | 2 | 2018 | 59536 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 4757 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 14889 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 4938 | 0.010 |
Why?
|
| Biopsy | 1 | 2007 | 3443 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2002 | 769 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 5112 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 4320 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2002 | 1271 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 10001 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2002 | 15694 | 0.000 |
Why?
|